Jennifer M. Day, PharmD
Coordinator, Emerging Therapeutics Strategy Program
Kaiser Permanente

Paying for Value
Pharmaceutical Evidence Landscape

Evidence

Understanding

Informed prescribing
Challenges to Assessing Value

• Type and amount of evidence available
  • Accelerated approvals and surrogate endpoints
  • Limited or unpublished data
  • Unknowns (e.g., long-term efficacy/safety, optimal dosing or duration)
  • FDA integrated review document?
• Delayed/incomplete post-market confirmatory studies
• Approved indications broader than that studied
Kaiser Permanente’s Integrated Model
Physician-Pharmacist Partnership

• Nationally 22,000 physicians

• National Pharmacy Services
  • Outpatient, Inpatient, and Clinic Administered Medication Services
  • Drug Information Services: internal support for clinicians in all care delivery sites
• Maintain goal of evidence-based treatment focusing on quality & safety

Strength of integrated medical and pharmaceutical services

• High level of collaboration between pharmacy and physicians
• Leverage physician expertise nationally
• Fully integrated electronic medical record
• Allows processes for reviewing and monitoring patients
KP Emerging Therapeutics Strategy Program
Proactive strategy development for select new and pipeline emerging therapies

1. Identify Drugs
2. Identify Key Stakeholders
3. Solicit Stakeholder Input
4. Formulate Strategy
5. Implement Strategy
6. Medication Use Reviews

INSTITUTE OF HEALTH POLICY FORUM
#DRUGPRICES  #KPIHP
What do we need to be successful?

- Maintain physician-pharmacy partnership
- Promote evidence-based medicine
- Avoid pressure to experiment in clinical practice
- Tighten standards for expedited review pathways
- Judicious use of real-world evidence in drug approval process
- Increase oversight of post-market studies
- Deter abuse of Orphan Drug Act